<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407965</url>
  </required_header>
  <id_info>
    <org_study_id>Adip-2010</org_study_id>
    <secondary_id>2010-024094-39</secondary_id>
    <nct_id>NCT01407965</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Carbapenem Antibiotics in Obese Patients.</brief_title>
  <official_title>Offene, Monozentrische, Nicht Kontrollierte Und Nicht Randomisierte Phase IV-Studie Zur Bestimmung Der Pharmakokinetik Von Carbapenemen in adipösen Patienten.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tissue kinetics of ertapenem and meropenem in fatty tissue, intraperitoneal fluid and plasma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the free tissue kinetics of ertapenem and meropenem
      in fatty tissue and intraperitoneal fluid up to 24 hours after administration of the IMP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unbound concentration of ertapenem and meropenem in fatty tissue and peritoneal fluid</measure>
    <time_frame>within 24 h after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (total and per patient)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (total and per patient)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Suspected Unexpected Serious Adverse Reactions (SUSARs)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Ertapenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free tissue kinetics of ertapenem in fatty tissue and intraperitoneal fluid in mg/L
Free and bound plasma concentration of ertapenem or meropenem in mg/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free tissue kinetics of meropenem in fatty tissue and intraperitoneal fluid in mg/L up to 24 hours after administration. Free and bound plasma concentration of meropenem in mg/L.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>microdialysis catheter</intervention_name>
    <description>Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity</description>
    <arm_group_label>Ertapenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>microdialysis catheter</intervention_name>
    <description>Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity</description>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized patients 18 years or older requiring elective surgical intervention (open
             or laparoscopic surgery) at intraabdominal organs

          -  BMI more or even 40

          -  written informed consent

        Exclusion Criteria:

          -  BMI &lt; 40

          -  pregnancy or lactation in women

          -  emergency surgery

          -  history of serious allergy or intolerance to β-lactam antibiotics

          -  systemic antimicrobial therapy with ceftazidime (internal standard of high-performance
             liquid chromatography / mass spectrometry) within a 7 days period prior to study entry

          -  ongoing intraabdominal infections

          -  terminal illness

          -  severe diseases of the liver, e.g. cirrhosis of the liver with ALT or AST &gt; 6 x upper
             limit of normal (ULN) and bilirubin &gt; 3 x ULN

          -  severe renal insufficiency with a creatinine clearance ≤30 mL/min.

          -  neutrophil count &lt; 1000 cells/mm3

          -  platelets &lt; 75000 cells/mm3

          -  coagulation studies (INR) &gt; 1.5 x ULN

          -  ongoing chemotherapy and/or radiotherapy

          -  ongoing therapy with valproin acid (in case of ertapenem administration).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doris Henne-Bruns, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mathias Wittau, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Ulm, Dept. of Visceral Surgery</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>August 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2011</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>M. Wittau</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>ertapenem</keyword>
  <keyword>meropenem</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Ertapenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

